| Case Title |
Lupin Limited: India's Leading Pharma Company |
| Case Author(s) |
Komal Chary Vivek Gupta
|
| University |
ICFAI Center for Management Research, India |
| Abstract |
The case presents the strategies adopted by Lupin Limited to emerge as one of the leading pharmaceutical companies in India. For the fiscal year 2004-05, Lupin reported revenues of Rs 12.12 billion, placing it among the top six companies in the Indian pharma industry. The company aims at achieving the revenues of US$ 1 billion by 2009. To achieve this target, Lupin has made heavy investments in R&D, manufacturing processes and is focusing on exports. Notwithstanding Lupin's success till date and its plans for future growth, the company faces significant threat in the form of product patents, high debts and rising competition from both local and foreign pharma companies. The case highlights the challenges facing Lupin and its plans to overcome these challenges. |
| Available In |
ECCH Case Collection |
| Publisher |
ICFAI Center for Management Research (ICMR) |
| Publisher Case No. |
306-333-1 |
| Distributor(s) |
European Case Clearing House
|
| Pub/Rev Date |
2005 |
| ISBN |
|
| Case Length |
14 pgs |
| Teaching Note |
Yes |
| Pub TN Ref No. |
306-033-8 |
| Pages (TN) |
4 pgs |
| Issues |
Growth Strategies of Lupin Limited; recent trends in Indian Pharmaceutical Industry; and product patent regime in India. |
| Organisation(s) |
Lupin Laboratories
|
| Countries |
India |
| Industry |
Healthcare & Pharmaceuticals |
| Period Covered |
1998 - 2005 |
| Level |
Postgraduate |
| Links of Interest |
Lupin's Website
|
| Back |